Neurocrine Biosciences Inc (NBIX)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $15.43B
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Latest financial period: June 30, 2026
Filed with the SEC: July 31, 2026
Estimated earnings date: October 27, 2026
Profit #334 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 77.6% | 77.8% | 71.0% | 71.7% |
Growth #106 of 1484 companies
Payout #1017 of 1484 companies
Safety #189 of 1484 companies
Price #515 of 1484 companies
